Synlogic is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of synthetic biotic. Co.'s pipeline includes: SYNB1934, which is an orally administered, non-systemically absorbed drug candidate based on a genetically engineered form of the probiotic E. coli Nissle; SYNB1353, which is a drug candidate designed to consume methionine, in the gastrointestinal (GI) tract thereby lowering homocysteine levels in patients with homocystinuria; SYNB8802, which is being developed for the treatment of enteric hyperoxaluria, a chronic, progressive disease; and SYNB2081, which is a synthetic biotic designed to consume uric acid in the GI tract. We show 27 historical shares outstanding datapoints in our coverage of SYBX's shares outstanding history.
Understanding the changing numbers of SYBX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SYBX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SYBX by allowing them to research SYBX shares outstanding history
as well as any other stock in our coverage universe. |
Free SYBX Email Alerts:
Video: Shares Outstanding Importance
